Luke Sergott
Stock Analyst at Barclays
(2.27)
# 2,514
Out of 5,182 analysts
380
Total ratings
40.93%
Success rate
-2.35%
Average return
Main Sectors:
Stocks Rated by Luke Sergott
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ICLR ICON Public Limited Company | Maintains: Equal-Weight | $200 → $120 | $106.81 | +12.35% | 24 | Mar 9, 2026 | |
| MEDP Medpace Holdings | Upgrades: Equal-Weight | $500 | $493.53 | +1.31% | 7 | Mar 6, 2026 | |
| PACB Pacific Biosciences of California | Downgrades: Underweight | $2 → $1.5 | $1.34 | +11.94% | 7 | Mar 6, 2026 | |
| IQV IQVIA Holdings | Upgrades: Overweight | $210 | $167.34 | +25.49% | 26 | Mar 6, 2026 | |
| CERT Certara | Downgrades: Equal-Weight | $8 | $5.55 | +44.14% | 22 | Mar 6, 2026 | |
| AVTR Avantor | Downgrades: Underweight | $8.5 | $7.90 | +7.59% | 29 | Mar 6, 2026 | |
| FTRE Fortrea Holdings | Maintains: Equal-Weight | $15 → $12 | $9.17 | +30.86% | 15 | Feb 27, 2026 | |
| A Agilent Technologies | Maintains: Overweight | $165 → $150 | $115.06 | +30.37% | 15 | Feb 26, 2026 | |
| RGEN Repligen | Maintains: Overweight | $200 → $175 | $120.10 | +45.71% | 5 | Feb 25, 2026 | |
| CRL Charles River Laboratories International | Maintains: Overweight | $215 → $200 | $175.65 | +13.86% | 12 | Feb 19, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $325 → $265 | $256.55 | +3.29% | 5 | Feb 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $55 → $50 | $37.59 | +33.01% | 9 | Feb 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Overweight | $400 | $320.00 | +25.00% | 19 | Feb 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $39 → $50 | $47.91 | +4.36% | 21 | Feb 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $115 → $118 | $89.79 | +31.42% | 13 | Feb 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $625 → $650 | $496.11 | +31.02% | 30 | Jan 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $52 | $40.89 | +28.10% | 3 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $230 → $270 | $193.03 | +39.87% | 6 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $1,600 → $1,550 | $1,325.01 | +16.98% | 4 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $100 → $110 | $120.93 | -9.04% | 22 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $85 → $120 | $78.60 | +52.67% | 6 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $17 → $22 | $23.27 | -5.46% | 15 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $19 → $20 | $15.36 | +30.21% | 23 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $225 → $250 | $189.61 | +31.85% | 41 | Oct 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $90 | $96.07 | -6.32% | 1 | Aug 1, 2025 |
ICON Public Limited Company
Mar 9, 2026
Maintains: Equal-Weight
Price Target: $200 → $120
Current: $106.81
Upside: +12.35%
Medpace Holdings
Mar 6, 2026
Upgrades: Equal-Weight
Price Target: $500
Current: $493.53
Upside: +1.31%
Pacific Biosciences of California
Mar 6, 2026
Downgrades: Underweight
Price Target: $2 → $1.5
Current: $1.34
Upside: +11.94%
IQVIA Holdings
Mar 6, 2026
Upgrades: Overweight
Price Target: $210
Current: $167.34
Upside: +25.49%
Certara
Mar 6, 2026
Downgrades: Equal-Weight
Price Target: $8
Current: $5.55
Upside: +44.14%
Avantor
Mar 6, 2026
Downgrades: Underweight
Price Target: $8.5
Current: $7.90
Upside: +7.59%
Fortrea Holdings
Feb 27, 2026
Maintains: Equal-Weight
Price Target: $15 → $12
Current: $9.17
Upside: +30.86%
Agilent Technologies
Feb 26, 2026
Maintains: Overweight
Price Target: $165 → $150
Current: $115.06
Upside: +30.37%
Repligen
Feb 25, 2026
Maintains: Overweight
Price Target: $200 → $175
Current: $120.10
Upside: +45.71%
Charles River Laboratories International
Feb 19, 2026
Maintains: Overweight
Price Target: $215 → $200
Current: $175.65
Upside: +13.86%
Feb 13, 2026
Maintains: Equal-Weight
Price Target: $325 → $265
Current: $256.55
Upside: +3.29%
Feb 13, 2026
Maintains: Overweight
Price Target: $55 → $50
Current: $37.59
Upside: +33.01%
Feb 11, 2026
Reinstates: Overweight
Price Target: $400
Current: $320.00
Upside: +25.00%
Feb 3, 2026
Maintains: Overweight
Price Target: $39 → $50
Current: $47.91
Upside: +4.36%
Feb 3, 2026
Maintains: Overweight
Price Target: $115 → $118
Current: $89.79
Upside: +31.42%
Jan 30, 2026
Maintains: Overweight
Price Target: $625 → $650
Current: $496.11
Upside: +31.02%
Dec 15, 2025
Maintains: Overweight
Price Target: $50 → $52
Current: $40.89
Upside: +28.10%
Dec 15, 2025
Maintains: Overweight
Price Target: $230 → $270
Current: $193.03
Upside: +39.87%
Dec 15, 2025
Maintains: Overweight
Price Target: $1,600 → $1,550
Current: $1,325.01
Upside: +16.98%
Dec 15, 2025
Maintains: Underweight
Price Target: $100 → $110
Current: $120.93
Upside: -9.04%
Dec 15, 2025
Maintains: Overweight
Price Target: $85 → $120
Current: $78.60
Upside: +52.67%
Dec 15, 2025
Maintains: Overweight
Price Target: $17 → $22
Current: $23.27
Upside: -5.46%
Nov 5, 2025
Maintains: Overweight
Price Target: $19 → $20
Current: $15.36
Upside: +30.21%
Oct 22, 2025
Maintains: Overweight
Price Target: $225 → $250
Current: $189.61
Upside: +31.85%
Aug 1, 2025
Initiates: Overweight
Price Target: $90
Current: $96.07
Upside: -6.32%